Qiubing Chen
- Pharmaceutical Science top 2%
- Advanced Drug Delivery Systems 6
- Molecular Medicine top 5%
- Curcumin's Biomedical Applications 6
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery 6
- Molecular Biology top 10%
- RNA Interference and Gene Delivery 9
- CRISPR and Genetic Engineering 6
-
- Nanoplatforms for cancer theranostics 7
-
- Inflammatory Bowel Disease 6
-
- Tea Polyphenols and Effects 4
- Journals
- Acta Pharmaceutica Sinica B (2 papers)ACS Applied Materials & Interfaces (2 papers)Colloids and Surfaces B Biointerfaces (2 papers)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Qiubing Chen
39 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Pharmaceutical Science 167
- Molecular Medicine 116
- Biomaterials 292
- Molecular Biology 1.1k
- Business and International Management 27
Countries citing papers authored by Qiubing Chen
This map shows the geographic impact of Qiubing Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiubing Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiubing Chen more than expected).
Fields of papers citing papers by Qiubing Chen
This network shows the impact of papers produced by Qiubing Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiubing Chen. The network helps show where Qiubing Chen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Qiubing Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 12 | |
| 3 | 2024 | 7 | |
| 4 | 2024 | 17 | |
| 5 | 2023 | 24 | |
| 6 | 2023 | 36 | |
| 7 | 2023 | 29 | |
| 8 | 2023 | 3 | |
| 9 | Tea leaf-derived exosome-like nanotherapeutics retard breast tumor growth by pro-apoptosis and microbiota modulationbreakdown → | 2023 | 124 |
| 10 | Fast and sensitive detection of SARS-CoV-2 RNA using suboptimal protospacer adjacent motifs for Cas12abreakdown → | 2022 | 272 |
| 11 | 2022 | 17 | |
| 12 | 2022 | 14 | |
| 13 | Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulationbreakdown → | 2021 | 233 |
| 14 | 2021 | 71 | |
| 15 | 2020 | 70 | |
| 16 | 2020 | 65 | |
| 17 | 2019 | 10 | |
| 18 | 2019 | 11 | |
| 19 | 2018 | 47 | |
| 20 | 2016 | 33 |
About Qiubing Chen
Qiubing Chen is a scholar working on Molecular Medicine, Pharmaceutical Science, Biomaterials, Biochemistry and Pathology and Forensic Medicine, having authored 40 papers that have together received 2.0k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (9 papers), Nanoplatforms for cancer theranostics (7 papers), Nanoparticle-Based Drug Delivery (6 papers), CRISPR and Genetic Engineering (6 papers), Advanced Drug Delivery Systems (6 papers), Curcumin's Biomedical Applications (6 papers), Inflammatory Bowel Disease (6 papers) and Tea Polyphenols and Effects (4 papers). The work is most often cited by research in Pharmaceutical Science (167 citations), Molecular Medicine (116 citations), Biomaterials (292 citations), Molecular Biology (1.1k citations) and Business and International Management (27 citations). Qiubing Chen has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Bo Xiao, Hao Yin, Yuejun Kang, Liang Zeng, Menghang Zu, Liyong Luo, Didier Merlin, Xinlin Lei, Zhigang Xu and Ying Zhang. Their work appears in journals such as Acta Pharmaceutica Sinica B, ACS Applied Materials & Interfaces, Colloids and Surfaces B Biointerfaces, Journal of Nanobiotechnology and Nature Biomedical Engineering.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.